JP2007533298A5 - - Google Patents

Download PDF

Info

Publication number
JP2007533298A5
JP2007533298A5 JP2006529654A JP2006529654A JP2007533298A5 JP 2007533298 A5 JP2007533298 A5 JP 2007533298A5 JP 2006529654 A JP2006529654 A JP 2006529654A JP 2006529654 A JP2006529654 A JP 2006529654A JP 2007533298 A5 JP2007533298 A5 JP 2007533298A5
Authority
JP
Japan
Prior art keywords
derivative
human
kda
polypeptide
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006529654A
Other languages
English (en)
Other versions
JP2007533298A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK2004/000686 external-priority patent/WO2005035565A1/en
Publication of JP2007533298A publication Critical patent/JP2007533298A/ja
Publication of JP2007533298A5 publication Critical patent/JP2007533298A5/ja
Withdrawn legal-status Critical Current

Links

Description

本発明の方法はまた、化学的に修飾されたIL-21組成物を使用する。ここでIL-21ポリペプチドは、ポリマー分子と連結する。具体的IL-21ポリペプチドは、機能的膜貫通ドメインを欠く可溶性ポリペプチド、たとえば成熟（mature）IL-21ポリペプチドである。典型的には、ポリマーは水溶性であり、IL-21結合体は水性環境、例えば生理学的環境において沈殿しない。適切なポリマーの例は、単一の反応基（例えば、アシル化のための活性エステルやアルキル化のためのアルデヒド）をもつように修飾されたポリマーである。ポリマーの重合度は調節することができる。反応性アルデヒドの例には、ポリエチレングリコールプロピオンアルデヒド、またはモノ-(C1-C10)アルコキシ、またはそのアリールオキシ誘導体がある（例えばHarris, et al., 米国特許番号5,252,714号を参照)。ポリマーの分岐の有無は問わない。さらに、ポリマーの混合物が、IL-21結合体を生成するために使用され得る。

Claims (9)

  1. （i）成熟（mature）IL-21ポリペプチドまたはＮ末端のMetを備えた成熟（mature）IL-21ポリペプチド；および
    （ii）少なくとも一つのSer, Tyr, LysまたはCysからなる1〜10個のアミノ酸の配列を介して前記IL-21ポリペプチドのＮ末端に連結された5 kDaまたは10 kDaの少なくとも二つのPEG分子
    からなるヒトIL-21の誘導体であって、
    少なくとも50 kDaの見かけのサイズを有するヒトIL-21の誘導体。
  2. 前記PEG分子が、Ser-hIL21に連結されている、請求項１に記載のヒトIL-21の誘導体。
  3. 請求項２に記載のヒトIL-21の誘導体を発現する単離されたDNA。
  4. 前記PEG分子が、5 kDaの重量を有する、請求項１に記載のヒトIL-21の誘導体。
  5. 前記PEG分子が、10 kDaの重量を有する、請求項１に記載のヒトIL-21の誘導体。
  6. 2〜8個のPEG分子が存在する、請求項１に記載のヒトIL-21の誘導体。
  7. 3〜6個のPEG分子が存在する、請求項６に記載のヒトIL-21の誘導体。
  8. 癌の治療のための薬物の製造のための、請求項１、２および４〜７の何れか一項に記載のヒトIL-21の誘導体の使用。
  9. 請求項１、２および４〜７の何れか一項に記載のヒトIL-21の誘導体を有効成分として含む、癌を治療するための薬学的組成物。
JP2006529654A 2003-10-10 2004-10-08 Ｉｌ−２１の誘導体 Withdrawn JP2007533298A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DKPA200301496 2003-10-10
US51089203P 2003-10-14 2003-10-14
DKPA200301529 2003-10-17
US51342203P 2003-10-22 2003-10-22
DKPA200400707 2004-05-04
US56956604P 2004-05-10 2004-05-10
PCT/DK2004/000686 WO2005035565A1 (en) 2003-10-10 2004-10-08 Il-21 derivatives

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2011087574A Division JP2011184442A (ja) 2003-10-10 2011-04-11 Ｉｌ−２１の誘導体
JP2011198348A Division JP2012067100A (ja) 2003-10-10 2011-09-12 Ｉｌ−２１の誘導体

Publications (2)

Publication Number Publication Date
JP2007533298A JP2007533298A (ja) 2007-11-22
JP2007533298A5 true JP2007533298A5 (ja) 2010-10-07

Family

ID=42779898

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006529654A Withdrawn JP2007533298A (ja) 2003-10-10 2004-10-08 Ｉｌ−２１の誘導体

Country Status (7)

Country Link
EP (2) EP2263684A1 (ja)
JP (1) JP2007533298A (ja)
CN (2) CN102516386A (ja)
AT (1) ATE481420T1 (ja)
CA (1) CA2542179A1 (ja)
DE (1) DE602004029173D1 (ja)
WO (1) WO2005035565A1 (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2642214T3 (es) * 2004-01-21 2017-11-15 Novo Nordisk Health Care Ag Conjugación de péptidos mediante transglutaminasa
US8034326B2 (en) 2005-04-18 2011-10-11 Novo Nordisk A/S IL-21 variants
EP1890723A2 (en) * 2005-06-06 2008-02-27 Novo Nordisk A/S Stabilised il-21 compositions
BRPI0615351A2 (pt) 2005-08-30 2011-05-17 Novo Nordisk Healthcare Ag formulações lìquidas de hormÈnio do crescimento peguilado
EP1966232A1 (en) 2005-12-23 2008-09-10 Novo Nordisk A/S Purification of proteins using preparative reverse phase chromatography (rpc)
AU2007271150A1 (en) 2006-07-07 2008-01-10 Novo Nordisk Health Care Ag New protein conjugates and methods for their preparation
US8475784B2 (en) 2006-10-26 2013-07-02 Novo Nordisk A/S IL-21 variants
JP2010512769A (ja) 2006-12-21 2010-04-30 ノヴォ ノルディスク アクティーゼルスカブ Ｉｌ−２１受容体との結合が変化したインターロイキン−２１変異体
WO2015000585A1 (en) * 2013-07-02 2015-01-08 Walter Sebald Muteins of cytokines of the gamma-chain receptor family conjugated to a non-protein group
CN105198999A (zh) * 2014-05-27 2015-12-30 上海生物制品研究所有限责任公司 一种融合蛋白、其制备方法及其应用
WO2020154187A1 (en) * 2019-01-21 2020-07-30 Sanofi Therapeutic rna for advanced stage solid tumor cancers
WO2024002170A1 (en) * 2022-06-29 2024-01-04 Beijing Neox Biotech Limited Il-21 polypeptides and methods of use
CN117645661A (zh) * 2022-09-02 2024-03-05 北京志道生物科技有限公司 一种聚乙二醇修饰的il-21衍生物及其应用

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
GB8430252D0 (en) 1984-11-30 1985-01-09 Beecham Group Plc Compounds
DE3676670D1 (de) 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
GB8610551D0 (en) 1986-04-30 1986-06-04 Hoffmann La Roche Polypeptide & protein derivatives
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
EP0325224B1 (en) 1988-01-22 1996-07-31 ZymoGenetics, Inc. Methods of producing secreted receptor analogs
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
GB8824591D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US4902502A (en) * 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
DE69034200T2 (de) 1989-04-19 2006-05-24 Enzon, Inc. Verfahren zum Herstellen von modifizierten Polypeptiden die eine Polypeptid und ein Polyalkylenoxid enthalten
EP0400472B1 (en) 1989-05-27 1996-04-03 Sumitomo Pharmaceuticals Company, Limited Process for preparing polyethylene glycol derivatives and modified protein.
US5219564A (en) 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
WO1992008790A1 (en) 1990-11-14 1992-05-29 Cargill, Incorporated Conjugates of poly(vinylsaccharide) with proteins for the stabilization of proteins
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
WO1992016555A1 (en) 1991-03-18 1992-10-01 Enzon, Inc. Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
AU674525B2 (en) * 1992-06-01 1997-01-02 Magainin Pharmaceuticals, Inc. Biologically active peptides having N-terminal substitutions
ZA933926B (en) 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
AU5006993A (en) 1992-08-21 1994-03-15 Enzon, Inc. Novel attachment of polyalkylene oxides to bio-effecting substances
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
NZ250375A (en) 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5298643A (en) 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
US5349001A (en) 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5321095A (en) 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
IL104734A0 (en) 1993-02-15 1993-06-10 Univ Bar Ilan Bioactive conjugates of cellulose with amino compounds
WO1994028024A1 (en) 1993-06-01 1994-12-08 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
AU7113594A (en) 1993-06-21 1995-01-17 Enzon, Inc. Site specific synthesis of conjugated peptides
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
EP0730470B1 (en) 1993-11-10 2002-03-27 Enzon, Inc. Improved interferon polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5473034A (en) 1994-03-18 1995-12-05 Hyogo Prefectural Government Method for producing protein-synthetic polymer conjugate and said conjugate produced thereby
US5629384A (en) 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
US5686110A (en) 1994-06-02 1997-11-11 Enzon, Inc. Water soluble complex of an alkyl or olefinic end capped polyalkylene oxide and a water insoluble substance
US5730990A (en) 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
EP0788375A2 (en) 1994-11-09 1997-08-13 Robin Ewart Offord Functionalized polymers for site-specific attachment
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
WO1996040248A1 (en) * 1995-06-07 1996-12-19 Eukarion, Inc. Transvacular and intracellular delivery of lipidized proteins
WO1996040791A1 (en) 1995-06-07 1996-12-19 Novo Nordisk A/S Modification of polypeptides
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US5747639A (en) 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
JP4410852B2 (ja) 1996-08-02 2010-02-03 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 単一の共有結合ｎ末端水溶性ポリマーを有するポリペプチド
JP2001508783A (ja) 1997-01-29 2001-07-03 ポリマスク・ファーマシューティカルズ・パブリック・リミテッド・カンパニー Ｐｅｇ化法
WO1998049198A1 (en) 1997-04-30 1998-11-05 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
RO121474B1 (ro) 1997-06-06 2007-06-29 Kyowa Hakko Kogyo Co., Ltd. Polipeptide modificate chimic
BR9812267B1 (pt) * 1997-07-14 2013-11-26 Hormônio de crescimento recombinante.
US5981709A (en) 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
EP1075282B1 (en) 1998-04-28 2005-06-15 Applied Research Systems ARS Holding N.V. Peg-lhrh analog conjugates
US20010023070A1 (en) * 1998-05-29 2001-09-20 Reinhard Ebner Interleukins-21 and 22
CA2329274A1 (en) * 1998-05-29 1999-12-02 Steven M. Ruben Interleukin-21
MXPA01009074A (es) * 1999-03-09 2002-03-27 Zymogenetics Inc Nuevo ligando zalfa11 de citocina.
CA2452582C (en) * 2001-07-11 2013-01-22 Maxygen Holdings, Ltd. G-csf conjugates
CA2460916A1 (en) * 2001-10-04 2003-04-10 Laura Carter Methods and compositions for modulating interleukin-21 receptor activity
ATE444363T1 (de) * 2001-11-05 2009-10-15 Zymogenetics Inc Il-21-antagonisten
AU2003230834A1 (en) 2002-04-09 2003-10-27 Beth Israel Deaconess Medical Center, Inc. Antagonists of il-21 and modulation of il-21-mediated t cell responses
ES2381265T3 (es) * 2002-06-07 2012-05-24 Zymogenetics, Inc. Uso de IL-21 y anticuerpo monoclonal para tratar cánceres sólidos
MXPA05000655A (es) 2002-07-15 2006-02-22 Harvard College Metodos y composiciones para modular el desarrollo y la funcion de las celulas t helper (th).
JP4664684B2 (ja) 2002-12-13 2011-04-06 ザイモジェネティクス， インコーポレイテッド 原核生物宿主におけるｉｌ−２１の生産
EP1653996A2 (en) * 2003-08-08 2006-05-10 Novo Nordisk Health Care AG Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest

Similar Documents

Publication Publication Date Title
Ding et al. Weak bond-based injectable and stimuli responsive hydrogels for biomedical applications
Zhang et al. Manipulation of hydrogel assembly and growth factor delivery via the use of peptide–polysaccharide interactions
TWI685347B (zh) 用於在活體中遞送ＲＮＡｉ觸發子至腫瘤細胞之聚結合物
JP2007533298A5 (ja)
US20200288709A1 (en) Composition with high antimicrobial activity and low toxicity
Huang et al. Marine-inspired molecular mimicry generates a drug-free, but immunogenic hydrogel adhesive protecting surgical anastomosis
Dong et al. Injectable adhesive hydrogel through a microcapsule cross-link for periodontitis treatment
JP2012126750A5 (ja)
JP2006513992A5 (ja)
JPH02191629A (ja) グラフト化ペプチド共重合体
TW200812572A (en) Polymer conjugate of taxane
WO2009152691A1 (zh) 聚乙二醇修饰壳寡糖脂肪酸嫁接物及制备方法和应用
Singh Dhillon et al. Recent development in applications of important biopolymer chitosan in biomedicine, pharmaceuticals and personal care products
Cui et al. Molecular engineering of antimicrobial peptide (AMP)–polymer conjugates
WO2010128672A1 (ja) 遺伝子組み換えゼラチンを含む血管新生誘導剤
JP2003321500A (ja) 新規なポリペプチドおよびその製造方法
Peng et al. Scarless wound closure by a mussel-inspired poly (amidoamine) tissue adhesive with tunable degradability
Asai et al. In situ depot formation of anti-HIV fusion-inhibitor peptide in recombinant protein polymer hydrogel
Gao et al. Immune enhancement of N-2-Hydroxypropyl trimethyl ammonium chloride chitosan/carboxymethyl chitosan nanoparticles vaccine
KR20210052473A (ko) 면역조정 특성을 갖는 펩티드
US20210023121A1 (en) Thrombin-responsive hydrogels and devices for auto-anticoagulant regulation
IL296230A (en) preparations to stop bleeding
JP3862361B2 (ja) 医療用手当材およびそれに用いる新規なペプチド
Li et al. Enzyme-Triggered Polyelectrolyte Complex for Responsive Delivery of α-Helical Polypeptides to Optimize Antibacterial Therapy
KR20210031478A (ko) 고분자 화합물 및 이를 이용한 세포내 화합물 도입 촉진제